中文名称:Anti-IL23 P19 antibody-白细胞介素23P19抗体英文名称:IL23 P19 品牌:沪震生物产地:中国/上海 保存条件:-20°C纯度规格:> 99% 产品类别:抗体 一抗 抗体名:Interleukin-23 subunit alpha; Il23a; IL 23; IL 23A; IL23P19; Interleukin 23 alpha subunit p19; JKA3 induced upon T cell activa...
Anti-IL-23p19 antibodyThe present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.ナバズニー,ジェラルドヘンリー...
抗体名: Research Grade Anti-Human IL23A/IL-23p19 (QX 004N) (对照抗体) 浓度: 1 mg/ml % 靶点: QX 004N 宿主: Human 用途: 仅用于科研 应用范围: 类似物,对照抗体 纯度: 95% 产地: France 品牌: AntibodySystem 货号: DHJ63111 用途: 类似物,对照抗体 亚型: IgG 是否单克隆...
An anti-IL23p19 monoclonal antibody (mAb) was developed by using hybridoma technology. Briefly, Balb/c mice were immunized with a recombinant mouse IL12p40/human IL23p19 complex. Finally, clone 17D1 was selected for its highest binding affinity to the hIL-23p19 subunit, but not against the...
Lyophilized formulatons of engineered anti-il-23p19 antibodies 本发明提供了抗体的冻干制剂,所述抗体例如特异性结合人白细胞介素-23p19(IL-23p19)的抗体或其抗原结合片段。 The present invention provides a lyophilized formulat... X Li,RS Kashi,A Badkar - WO 被引量: 3发表: 2009年 ...
methods for treating an autoimmune disease, inflammatory disease or proliferative disorder and psoriasis, and use of a solution formulation The present invention provides formulations in high concentration solution of anti-human interleukin-23 p19 hum13b8-b antibody (il-23p19), and its use in the ...
United States Patent US8263748 Note: If you have problems viewing the PDF, please make sure you have the latest version of Adobe Acrobat. Back to full textHome Search Services Contact us © 2004-2024 FreePatentsOnline.com. All rights reserved. Privacy Policy & Terms of Use....
Engineered antibodies to human IL-23p 19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.プレスタ, レオナード ジー.ベイヤー, ブライアン エム.イングラム, リチャード エヌ....
Inflammatory disorders, autoimmune disorders, and their use in the treatment of proliferative disorders is provided and such antibodies have been engineered to human IL-23p19. A binding compounds such as antibodies or fragments thereof, including binding to human IL-23p19, chimeric recombinant ...
The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg/ml of an anti-IL-23p19 antibody, wherein the antibody comprises a light chain amino acid sequence according to SEQ ID NO: 1 and a heavy chain amino acid sequence according to SEQ ID NO: 2;...